Castagna A - Search Results

1

Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series.

Messina E, Danise A, Ferrari G, Andolina A, Chiurlo M, Razanakolona M, Barakat M, Israel RJ, Castagna A. Messina E, et al. Among authors: castagna a. Infect Dis Ther. 2021 Dec;10(4):2791-2804. doi: 10.1007/s40121-021-00493-9. Epub 2021 Jul 23. Infect Dis Ther. 2021. PMID: 34302258 Free PMC article.

2

Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial.

Soria A, Danise A, Galli L, Tiberi S, Seminari E, Cossarini F, Bigoloni A, Marcotullio S, Lazzarin A, Castagna A. Soria A, et al. Among authors: castagna a. J Clin Virol. 2010 Mar;47(3):253-7. doi: 10.1016/j.jcv.2009.12.007. Epub 2010 Jan 6. J Clin Virol. 2010. PMID: 20056480 Clinical Trial.

3

Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs.

Hasson H, Merli M, Galli L, Gallotta G, Carbone A, Messina E, Bagaglio S, Morsica G, Salpietro S, Castagna A, Lazzarin A, Uberti-Foppa C. Hasson H, et al. Among authors: castagna a. Liver Int. 2013 Aug;33(7):1113-20. doi: 10.1111/liv.12159. Epub 2013 Mar 28. Liver Int. 2013. PMID: 23534616

4

Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients.

Merli M, Galli L, Castagna A, Salpietro S, Gianotti N, Messina E, Poli A, Morsica G, Bagaglio S, Cernuschi M, Bigoloni A, Uberti-Foppa C, Lazzarin A, Hasson H. Merli M, et al. Among authors: castagna a. New Microbiol. 2016 Apr;39(2):110-3. New Microbiol. 2016. PMID: 27196548 Free article.

5

Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.

Merli M, Galli L, Marinaro L, Ariaudo A, Messina E, Uberti-Foppa C, Castagna A, D'Avolio A, Lazzarin A, Bonora S, Hasson H. Merli M, et al. Among authors: castagna a. J Antimicrob Chemother. 2017 Mar 1;72(3):812-815. doi: 10.1093/jac/dkw492. J Antimicrob Chemother. 2017. PMID: 27999010

6

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.

Gianotti N, Poli A, Galli L, Franzin M, Tadini P, Galizzi N, Carbone A, Merli M, Muccini C, Oltolini C, Andolina A, Spagnuolo V, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: castagna a. PLoS One. 2017 Aug 1;12(8):e0182007. doi: 10.1371/journal.pone.0182007. eCollection 2017. PLoS One. 2017. PMID: 28763473 Free PMC article.

7

Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study.

Morsica G, Bagaglio S, Spagnuolo V, Castagna A, Di Serio C, Galli A, Della Torre L, Andolina A, Pramov A, Uberti-Foppa C. Morsica G, et al. Among authors: castagna a. PLoS One. 2017 Sep 1;12(9):e0184128. doi: 10.1371/journal.pone.0184128. eCollection 2017. PLoS One. 2017. PMID: 28863182 Free PMC article.

8

An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.

Galli L, Poli A, Muccini C, Galizzi N, Danise A, Spagnuolo V, Gianotti N, Carini E, Lazzarin A, Castagna A. Galli L, et al. Among authors: castagna a. Infect Dis (Lond). 2018 Mar;50(3):220-222. doi: 10.1080/23744235.2017.1374552. Epub 2017 Sep 11. Infect Dis (Lond). 2018. PMID: 28891371 No abstract available.

9

Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.

Gianotti N, Galli L, Galizzi N, Ripa M, Andolina A, Nozza S, Spagnuolo V, Poli A, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: castagna a. Int J Antimicrob Agents. 2018 Oct;52(4):492-499. doi: 10.1016/j.ijantimicag.2018.07.001. Epub 2018 Sep 13. Int J Antimicrob Agents. 2018. PMID: 30009958

10

Brief Report: Outcome of Acute Hepatitis B Virus Infection in HIV-1-Infected Patients: Possible Factors Associated With Resolution or Chronicity.

Morsica G, Galli L, Bossolasco S, Bagaglio S, Vercesi R, Salpietro S, Hasson H, Messina E, Castagna A, Uberti-Foppa C. Morsica G, et al. Among authors: castagna a. J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):175-180. doi: 10.1097/QAI.0000000000002106. J Acquir Immune Defic Syndr. 2019. PMID: 31192822

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,093 results

Search Page